Testing a new blood test for cancer detection
Part of Cancer clinical trials.
This study checks if a new blood test (PanTum Detect) can find cancer or pre-cancer. It compares results in people who may have cancer and in healthy people, using a PET/CT scan as a reference. This could lead to a simpler way to detect cancer early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 88 years old.
- You either have a suspected or confirmed solid tumor (Group A) or you are healthy with no known tumors (Group B).
- If you are in Group A, you must have had a PET/CT scan within a specific timeframe before or after your blood draw.
- You must be willing to give a blood sample for the test.
- You cannot have had recent surgery, injury, or certain medications (like steroids, chemotherapy, or antibiotics) within the last few weeks.
- You cannot have had any vaccinations in the last 4 weeks, or an active infection in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This study looks at “tumor regulatory molecules,” which are substances that may be released by cancer, to improve early pancreatic cancer detection. You may join if you have early, localized pancreatic cancer that can be treated with surgery, or certain pancreatic cysts/fluid collections where doctors are investigating further.
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Hear when a new Pre-malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.